doi: 10.1161/01.RES.0000250833.07254.8b
© 2006 American Heart Association, Inc.
Editorials |
CaM Kinase Inhibition
Apply Directly to the Heart?
From the Cardiovascular Institute, University of Pittsburgh, Pa.
Correspondence to Barry London, MD, PhD, Cardiovascular Institute, University of Pittsburgh, Scaife S572, 200 Lothrop Street, Pittsburgh, PA 15213-2582. Email londonb{at}upmc.edu
See related article, pages 1092–1099
Key Words: calcium • calmodulin • CaM kinase • arrhythmias • heart
Calcium/calmodulin-dependent protein kinases (CaM kinases) encompass a family of serine/threonine kinases (CaMKI-CaMKIV) that are regulated by calcium bound to calmodulin.1,2 Four separate genes encode the CaMKII subunits (
, ß, 
, 
), and 6 to 12 subunits homo- or heteromultimerize to form the active enzyme. Each subunit contains an N-terminal catalytic domain which binds ATP and substrate, a regulatory domain which includes an autoinhibitory domain and a Ca/Calmodulin binding domain, and a C-terminal association (multimerization) domain. In the heart, a number of splice variants of CaMKII are expressed, including CaMKII2 (CaMKIIC) and CaMKII3 (CaMKIIB) which differ from each other by the presence of a nuclear localization signal between the regulatory domain and the association domain in CaMKII3.3
CaMKII functions as a local calcium sensor in the heart. At baseline, the autoinhibitory domain prevents substrate binding to the enzyme.1,2 In cardiac myocytes, intracellular Ca2+ [Ca2+]i rises because of transmembrane influx through L-type Ca2+ channels (ICa) or the Na/Ca exchanger and release from internal stores such as the sarcoplasmic reticulum (SR). When intracellular Ca2+ rises, it binds to the EF-hand motifs at the N- and C-terminals calmodulin, an 
150 amino acid ubiquitous intracellular protein. The Ca/CaM complex then binds to the regulatory domain of CaMKII and removes the inhibition of the autoinhibitory domain. Of note, activated CaMKII can be autophosphorylated at Thr287, which allows the enzyme to remain in the active state in the absence of an elevated intracellular Ca2+. Ultimately, dephosphorylation by intracellular phosphatases returns the enzyme to the inactive state.
A number of cellular targets for CaMKII have been identified using in vitro expression systems, CaMKII inhibitors in vivo, and transgenic mice. Nuclear CaMKII3 activates a hypertrophic program via transcription factors such as CREB directly by phosphorylation and MEF2 indirectly by phosphyorylating class II histone deacetylases to release its inhibition.4,5 Cytoplasmic CaMKII2 associates with the L-type Ca2+ channel to allow Ca2+-dependent facilitation (an increase in ICa at increased stimulation frequencies) and phosphorylates the ryanodine receptor to increase SR leak.6,7 Thus, CaMKII activation can affect intracellular Ca2+ and alter its own activity.
Transgenic mice overexpressing of either CaMKII2 or CaMKII3 in the heart develop a dilated cardiomyopathy, with the phenotype being more severe for the cytoplasmic isoform.8,9 Transgenic overexpression of the CaMKII inhibitory peptide AC3-I, on the other hand, improves cardiac function and Ca2+ handling following myocardial infarction, protects against isoproterenol-induced hypertrophy and LV dysfunction, decreases phospholamban (PLN) phosphorylation at Thr17 and SR Ca2+ load, increases basal ICa, and eliminates Ca2+-dependent facilitation.10 Thus, CaMKII lies downstream from and parallels activation by the ß-adrenergic nervous system, suggesting that CaMKII blockade may have beneficial effects similar to ß-adrenergic blockers. In addition, CaMKII overexpression alters Ca2+ handling and ion channels in a way that would promote afterdepolarizations and arrhythmias. In a calcineurin overexpression mouse heart failure model, CaMKII suppression by KN93 reduces spontaneous arrhythmias, whereas CaMKII suppression by overexpression of AC3-I improves LV function and suppresses arrhythmias in Langendorff-perfused hearts.11
In the current issue of Circulation Research, Li et al study in detail the electrical remodeling in transgenic mice overexpressing the CaMKII inhibitory peptide AC3-I.12 AC3-I transgenic mice have shorter action potential durations (APDs) and QT intervals despite increased ICa because of upregulation of the inward rectifier current IK1 and the transient outward current Ito,f, with no significant changes in channel RNA or protein expression. These electrophysiological changes result from chronic AC3-I overexpression and are not reversed by modification of PKA activity nor mimicked by transient treatment of wild-type myocytes with AC3-I. Of note, the remodeling is eliminated when the AC3-I mice are crossed with PLN knockout mice, demonstrating that CaMKII-mediated alterations in PLN and, presumably, SR Ca2+ uptake/release are required for the electrical remodeling.
These findings extend our understanding of electrical remodeling in the heart. Most animal models and human studies of heart failure show APD prolongation because of decreases in outward K+ currents (usually Ito and IK1) or changes in ICa and its inactivation.13 APD prolongation could prolong ICa and preserve contractile force, although it increases the risk of triggered arrhythmias and could contribute to Ca2+ overload. The study by Li et al demonstrates that CaMKII inhibition at physiologically relevant levels can upregulate repolarizing K+ currents. This raises the possibility that manipulations that inhibit CaMKII could both improve ventricular function and reverse maladaptive electrical remodeling in conditions such as heart failure. In other words, CaMKII inhibition may be antiarrhythmic in a way analogous to ß-adrenergic blockade.
The mechanism by which CaMKII inhibition leads to increased K+ current expression is unknown. The absence of any change in RNA or protein levels suggests either an increase in surface expression or a posttranslational modification that increases current. CaMKII inhibition and changes in SR Ca2+ dynamics could modify a previously unrecognized ion channel, ion channel ß subunit, binding protein or a chaperone. Alternately, changes in CaMKII and SR Ca2+ handling could lead to posttranslational modifications in the ion channels themselves directly via mechanisms such as phosphorylation or indirectly via changes in adrenergic activity. Whereas Li et al showed that acute manipulations of PKA do not affect repolarizing current levels, they did not rule out the possibility that more chronic changes may have an impact. It is also possible that an unrecognized effect of the transgene could lead to the phenotype by a circuitous route, and it will be important to document similar findings in another model system.
A number of other questions also remain unanswered. It is not clear which CaMKII isoform is responsible for the major physiological effects. Similarly, the source of Ca2+ responsible for enzyme activation, the role of local changes in intracellular [Ca2+], and the importance of rapid versus slow changes in intracellular [Ca2+] are unknown. The applicability of finding in the mouse to those in larger animals and humans is uncertain. Direct relevance to prevention of arrhythmias and sudden death in a clinically relevant model needs to be shown.
In summary, Li et al have identified an unexpected feedback regulation involving CaMKII, PLN, and sarcolemmal K+ channels in the mouse. The mechanisms underlying this regulation will be important to discern. Time will tell, however, whether the findings can be applied to the arrhythmogenic human heart.
 |
Acknowledgments |
|---|
Sources of Funding
Funding from NIH-NHLBI HL062300 and HL077398, and an Established Investigator Award from the American Heart Association
Disclosures
None.
|
Footnotes |
|---|
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.
|
References |
|---|
 Top References |
|---|
1. Zhang T, Brown JH. Role of Ca2+/calmodulin-dependent protein kinase II in cardiac hypertrophy and heart failure. Cardiovasc Res. 2004; 63: 476–486.
2. Anderson ME. Calmodulin kinase signaling in heart: an intriguing candidate target for therapy of myocardial dysfunction and arrhythmias. Pharmacol Ther. 2005; 106: 39–55.[CrossRef][Medline] [Order article via Infotrieve]
3. Hoch B, Meyer R, Hetzer R, Krause E-G, Karczewski P. Identification and expression of -isoforms of the multifunctional Ca2+/calmodulin-depedent protein kinase in failing and nonfailing human myocardium. Circ Res. 1999; 84: 713–721.
4. Sheng M, Thompson MA, Greenberg ME. CREB: a Ca2+-regulated transcription factor phosphorylated by calmodulin-dependent kinases. Science. 1991; 252: 1427–1430.
5. Lu J, McKinsey TA, Nicol RL, Olson EN. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc Natl Acad Sci U S A. 2000; 97: 4070–4075.
6. Anderson MD, Braun AP, Shulman H, Premack BA. Multifunctional Ca2+/calmodulin-dependent protein kinase mediates Ca2+-induced enhancement of the L-type Ca2+ current in rabbit ventricular myocytes. Circ Res. 1994; 75: 854–861.
7. Wehrens XH, Lehnart SE, Reiken SR, Marks AR. Ca2+/calmodiulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res. 2004; 94: E61–E70.[CrossRef][Medline] [Order article via Infotrieve]
8. Zhang T, Johnson EN, Gu Y, Morissette MR, Sah VP, Gigena MS, Belke DD, Dillmann WH, Rogers TB, Shulman H, Ross J Jr., Brown JH. The cardiac-specific nuclear B isoform of Ca2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J Biol Chem. 2002; 277: 1261–1267.
9. Zhang T, Maier LS, Dalton ND, Miyamoto S, Ross J Jr., Bers DM, Brown JH. The C isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res. 2003; 92: 912–919.
10. Zhang R, Khoo MSC, Wu Y, Yang Y, Grueter CE, Ni G, Price EE Jr., Their W, Guatimosim S, Song L-SS, Madu EC, Shah AN, Vishnivetskaya TA, Atkinson JB, Gurevich VV, Salama G, Lederer WJ, Colbran RJ, Anderson ME. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med. 2005; 11: 409–417.[CrossRef][Medline] [Order article via Infotrieve]
11. Khoo MSC, Li J, Singh MV, Yang Y, Kannankeril P, Wu Y, Grueter CE, Guan X, Oddis CV, Zhang R, Mendes L, Ni G, Madu EC, Yang J, Bass M, Gomez RJ, Wadzinski BE, Olson EN, Colbran RJ, Anderson ME. Death, cardiac dysfunction, and arrhythmias are increased by calmodulin kinase II in calcineurin cardiomyopathy. Circulation. 2006; 114: 1352–1359.
12. Li J, Marionneau C, Zhang R, Shah V, Hell JW, Nerbonne JM, Anderson ME. Calmodulin kinase II inhibition shortens action potential duration by up-regulation of K+ currents. Circ Res. 2006; 99: 1092–1099.
13. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res. 2004; 95: 754–763.
Related Article:
Circ. Res. 2006 99: 1092-1099.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||